Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kamada ( (IL:KMDA) ) has issued an update.
Kamada Ltd. reported strong financial results for the first quarter of 2025, with a 17% increase in revenues to $44 million and a 54% rise in adjusted EBITDA to $11.6 million compared to the previous year. The company announced the expansion of its plasma collection operations with a new site in San Antonio, Texas, and launched a post-marketing research program for CYTOGAM®. Kamada is reiterating its full-year 2025 guidance, expecting revenues between $178 million and $182 million and adjusted EBITDA between $38 million and $42 million. The company’s strategic initiatives, including M&A and the advancement of its Phase 3 Inhaled AAT program, are expected to support continued growth.
The most recent analyst rating on (IL:KMDA) stock is a Hold with a ILs13.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in the development and commercialization of specialty plasma-derived products. The company focuses on rare and serious conditions and operates in the specialty plasma-derived field.
Average Trading Volume: 89,267
Current Market Cap: ILs1.39B
See more data about KMDA stock on TipRanks’ Stock Analysis page.